Literature DB >> 20137269

[Association of ENA-78, IP-10 and VEGF gene polymorphism with idiopathic pulmonary fibrosis].

Long Liu1, Hua-Ping Dai, Bai Xiao, Shu Zhang, Cheng-Jun Ban, Ping Xin.   

Abstract

OBJECTIVE: To examine whether there was an association between epithelial neutrophil activating peptide 78 (ENA-78), interferon-inducible protein 10 (IP-10), vascular endothelial growth factor (VEGF) polymorphism and Chinese patients with idiopathic pulmonary fibrosis (IPF).
METHODS: Polymerase chain reaction (PCR) and restriction fragment length polymorphism (RFLP) were performed to analyze the gene polymorphisms of ENA-78 (-156G/C), IP-10 (-1596C/T) and VEGF (+405G/C) in 60 IPF patients and 60 controls with trauma or bone fracture matched in age, gender and smoking status.
RESULTS: The distribution of carrying GC + CC genotype frequency (20.0%) and C allele frequency (12.7%) for ENA-78 in IPF patients was significantly higher than that in healthy controls [6.7% (P = 0.032) and 3.3% (P = 0.008), respectively], the relative risk of suffering from IPF of -156C allele gene carrier significantly increased (OR = 4.23, 95%CI: 1.35-13.20). The distribution of carrying CT + TT genotype frequency (10.0%) and T allele frequency (5.8%) for IP-10 in IPF patients was significantly lower than that in healthy controls [26.7% (P = 0.018) and 14.2% (P = 0.031), respectively], the relative risk of suffering from IPF of -1596T allele gene carrier decreased (OR = 0.38, 95%CI: 0.15-0.95). No association was found between VEGF (+405G/C) polymorphism and IPF.
CONCLUSIONS: -156C allele for ENA-78 may be a risk factor of IPF and -1596T allele for IP-10 a beneficial factor of IPF. The VEGF (+405G/C) gene polymorphism has no effect upon the predisposition to IPF.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20137269

Source DB:  PubMed          Journal:  Zhonghua Yi Xue Za Zhi        ISSN: 0376-2491


  5 in total

Review 1.  Type 2 macrophages and Th2 CD4+ cells in interstitial lung diseases (ILDs): an overview.

Authors:  Neftali Partida-Zavala; Marco Antonio Ponce-Gallegos; Ivette Buendía-Roldán; Ramcés Falfán-Valencia
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2018-04-28       Impact factor: 0.670

Review 2.  Evolving genomic approaches to idiopathic pulmonary fibrosis: moving beyond genes.

Authors:  Daniel J Kass; Naftali Kaminski
Journal:  Clin Transl Sci       Date:  2011-10       Impact factor: 4.689

Review 3.  Biomarkers in idiopathic pulmonary fibrosis.

Authors:  Yingze Zhang; Naftali Kaminski
Journal:  Curr Opin Pulm Med       Date:  2012-09       Impact factor: 3.155

Review 4.  Personalized medicine: applying 'omics' to lung fibrosis.

Authors:  Jose D Herazo-Maya; Naftali Kaminski
Journal:  Biomark Med       Date:  2012-08       Impact factor: 2.851

5.  Role of VEGF Polymorphisms in the Susceptibility and Severity of Interstitial Lung Disease.

Authors:  Sara Remuzgo-Martínez; Fernanda Genre; Verónica Pulito-Cueto; Belén Atienza-Mateo; Víctor Manuel Mora Cuesta; David Iturbe Fernández; Sonia María Fernández Rozas; Leticia Lera-Gómez; Pilar Alonso Lecue; María Piedad Ussetti; Rosalía Laporta; Cristina Berastegui; Amparo Solé; Virginia Pérez; Alicia De Pablo Gafas; Oreste Gualillo; José Manuel Cifrián; Raquel López-Mejías; Miguel Ángel González-Gay
Journal:  Biomedicines       Date:  2021-04-22
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.